Peristaltic Pump Microfluidics OoC — PatSnap Eureka
Scaling Peristaltic Pump Microfluidics for Organ-on-Chip Platforms
From dead volume and pulsatility to multi-organ state-machine complexity — a patent-backed analysis of the engineering obstacles blocking practical deployment of peristaltic-driven organ-on-chip systems at scale. Drawing from 20 patent records across the US, China, India, and PCT jurisdictions.
Why Peristaltic Pump Scaling Is an Unsolved Engineering Problem
The dataset for this analysis encompasses patents and applications from institutions including Vanderbilt University, Harvard College, Emulate Inc., the Indian Institute of Science, the Chinese Academy of Sciences (Shanghai and Dalian branches), Tsinghua University's Shenzhen Graduate School, Zhengzhou University, and Hainan University, among others — a total of 20 patent records across US, China, India, and PCT jurisdictions filed between 2013 and 2026.
The dominant technical approaches cluster around three paradigms: on-chip pneumatically actuated peristaltic micropumps using deformable PDMS membranes, rotary planar peristaltic micropumps (RPPMs) with external motor-driven bearing assemblies, and gravity-driven or rocking-platform alternatives that bypass active pumping altogether. A fourth emerging approach uses biological actuators — specifically cardiomyocyte contraction — as the pump driving force.
The recurring engineering challenges across all these approaches include flow pulsatility, dead volume management, material compatibility, multi-organ fluidic interconnection, sterility, and miniaturized control electronics. These challenges intensify substantially when moving from single-organ chips to integrated multi-organ systems operating in parallel at high throughput. The life sciences innovation intelligence tools available on PatSnap are increasingly being used to track how these challenges evolve across assignees and jurisdictions.
Regulatory bodies including the US FDA have signaled growing interest in organ-on-chip technologies as alternatives to animal testing, making the resolution of these scaling challenges commercially urgent.
Dead Volume, Pulsatility, and Flow Uniformity at Scale
One of the most fundamental scaling challenges is that peristaltic pumping inherently generates pulsatile flow rather than steady laminar flow — with cascading consequences across multi-organ configurations.
Pulse Artifacts Distort Downstream Tissue Environments
In single-organ chips, pulsatility may be tolerable or even physiologically relevant for mimicking cardiovascular shear stress. However, in multi-organ configurations linking several chambers in series, pulse artifacts propagate and distort the fluidic environment of downstream tissues. The Vanderbilt RPPM design uses a rolling-member bearing assembly on a circular fluidic path to reduce pulsatility relative to classic three-valve pneumatic designs — but introduces new mechanical tolerance requirements at microscale.
Vanderbilt RPPM, 2018Long Tubing Dilutes Paracrine Signals Below Detection
Long external tubing between off-chip pumps and individual organ chambers dilutes secreted cytokines and other paracrine signaling molecules to sub-detectable concentrations — a critical limitation for drug metabolism and inter-organ crosstalk studies. The CAS Shanghai micropump patent (2025) explicitly identifies this as the core argument for on-chip or plug-and-play pump architectures, noting that long and numerous fluid tubes not only waste culture medium but dilute cytokines secreted by cells, tissues, or organs, hindering detection of secreted substances.
CAS Shanghai, 2025Plug-and-Play Integration Multiplies Valve and Actuator Count
The plug-and-play approach collapses tubing length to near-zero but introduces its own scaling challenge: each organ unit requires its own dedicated pump assembly with its own electromagnetic solenoid valve. Multiplying this architecture across a high-throughput array rapidly increases part count, interconnect complexity, and the probability of valve failure. Pneumatic three-valve peristaltic designs require at least three pneumatic channels and three solenoid valves per pump unit, making part-count scaling unfavorable.
CAS Shanghai micropump, 2025Parallel Culture Modules Demand Micrometer-Scale Channel Tolerances
Delivering identical flow rates to each of several parallel culture modules through a shared fluidic network requires either precise passive resistance balancing — a function of channel geometry tolerances at the micrometer scale — or active flow control at each branch. The CAS Shanghai high-throughput organ-on-chip (2022) describes a multi-module chip with open and closed culture layers separated by a porous membrane, instrumented with electrode layers for transepithelial electrical resistance (TEER) measurement, where flow uniformity is critical for measurement validity.
CAS Shanghai TEER chip, 2022Innovation Activity Across Institutions and Approaches
Visual analysis of the 20-patent dataset reveals clear geographic clustering and a progressive shift in pump integration strategy over the 2013–2026 filing period.
Patent Activity by Key Assignee
Vanderbilt University leads with 5 active/inactive US patents covering integrated OoC platforms. CAS contributes 4 patents across two institutes with complementary approaches.
Filing Timeline: Integration Strategy Shift
The trend across the dataset shows a progressive shift from external peristaltic pumps toward on-chip or plug-and-play pump integration, driven by the dead-volume and cytokine dilution problem.
Fabrication Constraints That Intensify at Scale
The dominant material in OoC fabrication — PDMS — presents several problems when integrated with peristaltic pump elements at manufacturing scale, while alternative actuation materials introduce their own constraints.
PDMS Dual-Role Membrane Variance
The CAS Dalian all-PDMS four-layer architecture uses a porous elastic membrane that serves dual duty as both the gas-liquid interface for in-line peristaltic pump function and the diffusion barrier between culture chambers. Achieving consistent mechanical compliance across a 1-to-10 unit parallel array is non-trivial in soft-lithography manufacturing, where membrane thickness can vary by tens of microns — enough to cause inter-module leakage or actuation failure.
SMA Thermal Crosstalk in Actuator Arrays
The Indian Institute of Science SMA peristaltic pump (2026) eliminates pneumatic supply lines and solenoid valves — a significant simplification — but SMA actuators cycle between austenite and martensite phases by Joule heating and passive cooling. At microscale and in a biologically relevant temperature window of 37°C ± 0.5°C, heat generated during actuation must be precisely dissipated without disturbing cell culture temperature. Scaling from a single pump unit to an array amplifies this thermal coupling problem substantially.
Fluidic Control Architecture and State-Machine Complexity
Connecting multiple organ units in series or parallel demands a routing architecture capable of directing, recirculating, bypassing, or sampling effluent without cross-contamination or flow imbalance.
| Challenge | Technical Detail | Source Patent | Scaling Impact |
|---|---|---|---|
| Bypass mode switching | Perfusion controller operates in three distinct modes including a bypass configuration where Organ N is disconnected and effluent flows directly from Organ N−1 to Organ N+1. | Vanderbilt, 2013 | Requires valves at each node |
| Independent pump/valve addressing | Each bio-object microfluidics module contains one or more on-chip pumps, a plurality of fluidic switches, and a power and control unit adapted for selectively and individually controlling each pump and switch. | Vanderbilt, 2018 | Combinatorial explosion at 10+ organs |
| Per-organ drug injection | A drug is injected only into Organ N while media continues to flow through the broader circuit. Requires flow isolation during injection and temporary pump interruption at a specific node without disrupting pressure equilibrium elsewhere. | Vanderbilt, 2018 | Hydraulic pressure transients propagate network-wide |
| TEER measurement integrity | Pressure transients from pump start/stop events at one node propagate as hydraulic waves through the entire fluidic network, potentially introducing measurement artifacts in TEER sensors. | CAS Shanghai, 2022 | Sensor noise scales with organ count |
| Drop-to-drop manifold connections | Emulate's perfusion manifold assembly proposes a detachable manifold with a drop-to-drop connection scheme that optionally eliminates tubing entirely, delivering fluid from a reservoir to chip ports at a controllable flow rate. | Emulate, 2019 | Relocates dead volume to manifold junctions |
Map the full multi-organ control architecture patent space
PatSnap Eureka's AI tools surface claim-level insights across the entire OoC control architecture filing history.
Geographic and Institutional Clustering of Innovation
The patent data reveals a clear geographic and institutional clustering of innovation, with Vanderbilt University as the most prolific assignee and the Chinese Academy of Sciences appearing through two complementary institutes.
Vanderbilt University
At least four active or inactive US patents covering integrated OoC platforms with on-chip pumps, fluidic switches, and multi-organ routing architectures, reflecting a sustained program of platform-level engineering. The RPPM design and multi-organ bypass/drug injection routing architectures are the flagship contributions. The patent analytics tools on PatSnap track the full Vanderbilt continuation chain across jurisdictions.
RPPM · Multi-organ routing · Drug injection nodesChinese Academy of Sciences
The Shanghai Institute of Microsystem and Information Technology focuses on plug-and-play micropump integration and high-throughput electrode-instrumented chips (2022 TEER chip). The Dalian Institute of Chemical Physics focuses on in-line pneumatic peristaltic pump integration within all-PDMS multi-organ chips (2020, 2022). Together they represent the most active non-US filing program in this dataset. The materials science intelligence tools on PatSnap cover PDMS and advanced polymer filings globally.
Plug-and-play micropump · TEER electrode chip · All-PDMS 4-layerIndian Institute of Science
Notable for two complementary contributions: the SMA-actuated peristaltic pump apparatus (2026), representing a departure from pneumatic actuation paradigms, and a separate organ-on-chip device for establishing tissue or organ architecture (2025) that uses a distensible membrane and reservoir-based hydrodynamic pressure to drive perfusion. Together these filings represent the most novel actuation approach in the dataset from an engineering standpoint.
SMA actuation · Hydrodynamic pressure perfusion · 2025–2026Emulate, Inc. & Harvard College
Emulate represents the commercial translation end of the spectrum, with a perfusion manifold assembly granted in both Canada and the US, focusing on user workflow simplification and tubing-free connections. Harvard College contributed an early foundational WO filing (2013) describing cartridge-based organ chips with separate perfusion controllers and pneumatic control — an architecture that influenced many subsequent designs. The customer case studies on PatSnap show how commercial teams use Eureka to track competitor IP.
Manifold assembly · Drop-to-drop connections · Foundational WO 2013Seven Engineering Conclusions From the Patent Record
The 20-patent dataset yields a consistent set of engineering conclusions that span actuation paradigm, material choice, and system architecture. The trend visible across the dataset is a progressive shift from external peristaltic pumps connected by long tubing, toward on-chip or plug-and-play pump integration, driven primarily by the dead-volume and cytokine dilution problems identified consistently across multiple assignees.
Key conclusions traceable to specific filings include: (1) dead volume and cytokine dilution are the primary driver of pump integration; (2) pneumatic three-valve peristaltic designs trade external pumps for external valves; (3) rotary planar peristaltic micropumps reduce pulsatility but demand microscale mechanical precision; (4) multi-organ bypass and drug injection routing create state-machine complexity; (5) biological actuation solves power delivery but introduces reproducibility challenges; (6) SMA actuator arrays must manage thermal crosstalk within the 37°C cell culture environment; and (7) manifold-based fluid delivery simplifies user workflow but relocates the scaling problem to hydraulic resistance uniformity across polymer-molded interfaces.
For researchers and engineers working in this space, PatSnap Eureka provides AI-assisted claim mapping across all 20 source patents and thousands of related filings. The NIH's organ-on-chip research program and WIPO's patent database provide additional context for the global filing landscape. For developer access to PatSnap's underlying data, the PatSnap Open API enables programmatic integration.
Peristaltic Pump Microfluidics for Organ-on-Chip — Key Questions Answered
Peristaltic pumping inherently generates pulsatile flow rather than steady laminar flow. In multi-organ configurations linking several chambers in series, pulse artifacts propagate and distort the fluidic environment of downstream tissues.
Long external tubing between off-chip pumps and individual organ chambers dilutes secreted cytokines and other paracrine signaling molecules to sub-detectable concentrations — a critical limitation for drug metabolism and inter-organ crosstalk studies.
The rotary planar peristaltic micropump (RPPM) uses a rolling-member bearing assembly that compresses a circular fluidic path, converting continuous shaft rotation into fluid displacement between two ports. While this design reduces pulsatility relative to classic three-valve pneumatic designs, it introduces new challenges: the mechanical tolerances required for the rolling-member/fluidic-path interface must be maintained at microscale across multiple pump units operating simultaneously on a single integrated platform.
SMA actuators cycle between austenite and martensite phases by Joule heating and passive cooling; at microscale and in a biologically relevant temperature window (37°C ± 0.5°C), the heat generated during actuation must be precisely dissipated without disturbing the cell culture temperature. Scaling from a single pump unit to an array of pumps on one substrate amplifies this thermal coupling problem substantially.
The pump output is entirely dependent on the viability, maturation state, and beating rate of the cardiomyocytes, which are inherently variable between batches and deteriorate over culture time — a fundamental reproducibility challenge that becomes more severe as platform scale increases.
Enabling per-organ drug injection and bypass requires independent pump and valve control at every node, creating exponential growth in control complexity as organ count increases. Scaling this architecture to 10 or more organ modules creates a combinatorial explosion in the number of addressable elements and the complexity of the state machine required to manage them.
Still have questions about OoC pump engineering? Let PatSnap Eureka answer them for you.
Ask Eureka AI Your R&D QuestionAccelerate Your Organ-on-Chip R&D with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to navigate complex microfluidics and biomedical device patent landscapes faster.
References
- Organ on chip integration and applications of the same — Vanderbilt University, 2018
- Organ on chip integration and applications of the same — Vanderbilt University, 2018
- Integrated organ-on-chip systems and applications of the same — Vanderbilt University, 2018
- Integrated organ-on-chip systems and applications of the same — Vanderbilt University, 2014
- Integrated organ-on-chip system and applications of the same — Vanderbilt University, 2013
- Micropump for organ-on-chip and its fabrication and use methods and liquid delivery system — Chinese Academy of Sciences, Shanghai Institute of Microsystem and Information Technology, 2025
- High-throughput organ-on-chip and its applications — Chinese Academy of Sciences, Shanghai Institute of Microsystem and Information Technology, 2022
- Multi-organ chip based on microfluidic technology and its applications — Chinese Academy of Sciences, Dalian Institute of Chemical Physics, 2022
- Multi-organ chip based on microfluidic technology and its applications — Chinese Academy of Sciences, Dalian Institute of Chemical Physics, 2020
- Cardiomyocyte micropump-driven self-circulating organ chip dynamic culture device — Tsinghua University Shenzhen Graduate School, 2018
- Peristaltic pump apparatus and method for generating peristaltic displacement of fluid through flexible fluid conduit — Indian Institute of Science, 2026
- An organ-on-chip device for establishing a tissue or organ architecture — Indian Institute of Science, 2025
- Perfusion manifold assembly — Emulate, Inc., 2019
- Perfusion manifold assembly — Emulate, Inc., 2017
- Integrated human organ-on-chip microphysiological systems — President and Fellows of Harvard College, 2013
- Cardiac organoid-PDMS microfluidic chip in vitro circulation culture system and construction method — Zhengzhou University, 2025
- Microfluidic intestinal organ chip, construction method and application — Hainan University, 2025
- NIH — Organ-on-Chip Research Program and PDMS microfluidics literature
- WIPO — International Patent Database for OoC and Microfluidics Filings
- US FDA — Organ-on-Chip Technology and Alternative Testing Methods
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.